Document is current
Any future updates will be listed below
-
Authors
Ter Maat, Laurens S.
De Mooij, Rob A. J.
Van Duin, Isabella A. J.
Verhoeff, Joost J. C.
Elias, Sjoerd G.
Leiner, Tim
van Amsterdam, Wouter A. C.
Troenokarso, Max F.
Arntz, Eran R. A. N.
Van den Berkmortel, Franchette W. P. J.
Boers-Sonderen, Marye J.
Boomsma, Martijn F.
Van den Eertwegh, Fons J. M.
de Groot, Jan Willem
Hospers, Geke A. P.
Piersma, Djura
Vreugdenhil, Art
Westgeest, Hans M.
Kapiteijn, Ellen
De Wit, Ardine A.
Blokx, Willeke A. M.
Van Diest, Paul J.
De Jong, Pim A.
Pluim, Josien P. W.
Suijkerbuijk, Karijn P. M.
Veta, Mitko
-
Funding
Funding for this research was provided by:
The Netherlands Organization for Health Research and Development (848101007, 848101007, 848101007, 848101007, 848101007, 848101007, 848101007, 848101007, 848101007, 848101007)
Philips
- License Information
-
More Information
Article History
Received: 2 April 2024
Accepted: 25 November 2024
First Online: 30 December 2024
Declarations
:
: AvdE has advisory relationships with Bristol-Myers Squibb, MSD Oncology, Amgen, Roche, Novartis, Sanofi, Pfizer, Ipsen, Merck, Pierre Fabre and has received research study grants not related to this paper from Sanofi, Bristol-Myers Squibb, TEVA, Idera and has received travel expenses MSD Oncology, Roche, Pfizer, Sanofi, Pierre Fabre and has received speaker honoraria from BMS and Novartis. JdG has consultancy/advisory relationships with Bristol Myers Squibb, Pierre Fabre, Servier, MSD, Novartis. PJ has a research collaboration with Philips Healthcare and Vifor Pharma. MBS has consultancy/advisory relationships with Pierre Fabre, MSD and Novartis, none related to current work and paid to institute. EK has consultancy/advisory relationships with Bristol Myers Squibb, Novartis, Merck, Pierre Fabre, Lilly, Bayer, EISAI and Ipsen paid to the institute, and received research grants not related to this paper from Bristol Myers Squibb, Delcath, Novartis and Pierre Fabre. PD has consultancy/advisory relationships with Paige, Pantarei and Samantree paid to the institution and research grants from Pfizer, none related to current work and paid to institute. KS has advisory relationships with Bristol Myers Squibb, Novartis, MSD, Pierre Fabre, AbbVie, Sairopsa and received honoraria from Novartis and MSD and research funding from Bristol Myers Squibb, TigaTx and Philips. TL has received research funding from Philips. GH consultancy/advisory relationships with Amgen, Bristol-Myers Squibb, Roche, MSD, Pfizer, Novartis, Sanofi, Pierre Fabre and has received research grants from Bristol-Myers Squibb, Seerave. All payments to the Institution. HW received honoraria from Merck, Astellas, Roche and travel expenses from Ipsen and Astellas. All remaining authors have declared no conflicts of interest.
